Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 7/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26280853 | 1.00 | PDK1 (0.51) | PDK1EPHA2ERBB2SMN1; SMN2DRD4 | |
| SCHEMBL29762067 | 0.90 | PDK1 (0.54) | PDK1DRD4HRH3 | |
| SCHEMBL26621715 | 0.88 | PDK1 (0.49) | PDK1DRD4HRH3 | |
| SCHEMBL23560447 | 0.88 | PDK1 (0.49) | PDK1DRD4HRH3 | |
| SCHEMBL24764354 | 0.87 | PDK1 (0.48) | PDK1DRD4HRH3 | |
| SCHEMBL23945669 | 0.87 | PDK1 (0.48) | PDK1DRD4HRH3 | |
| SCHEMBL24508708 | 0.85 | ALDH1A1 (0.41) | PDK1EPHA2ERBB2SMN1; SMN2DRD4 | |
| SCHEMBL22802807 | 0.85 | ALDH1A1 (0.41) | PDK1EPHA2ERBB2SMN1; SMN2DRD4 | |
| SCHEMBL22802803 | 0.85 | ALDH1A1 (0.41) | PDK1EPHA2ERBB2SMN1; SMN2DRD4 | |
| SCHEMBL25828289 | 0.85 | PDK1 (0.46) | PDK1EPHA2ERBB2SMN1; SMN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PDK1 1599/4885EPHA2 1822/4885ERBB2 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.